VYONDYS 53

golodirsen · Sarepta Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for VYONDYS 53, covering 2019-12-12 to 2025-11-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) [Phase 3]

See pricing